Loading...
Docoh

Danaher (DHR)

Danaher Corporation is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 69,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.

Company profile

Ticker
DHR, DHR+B
Exchange
Website
CEO
H. Lawrence Culp
Employees
Incorporated
Fiscal year end
Former names
DMG INC
SEC CIK
Subsidiaries
AB Sciex LLC • AB Sciex LP • AB Sciex Pte Ltd. • Aldevron, L.L.C. • Applitek NV • Aquatic Infomatics ULC • BC Distribution BV • Beckman Coulter Australia Pty Ltd • Beckman Coulter Biotechnology (Suzhou) Co. Ltd. • Beckman Coulter Canada LP ...
IRS number
591995548

DHR stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

20 Jul 22
1 Oct 22
31 Dec 22
Quarter (USD) Jul 22 Apr 22 Dec 21 Oct 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.98B 3.98B 3.98B 3.98B 3.98B 3.98B
Cash burn (monthly) (no burn) 278.17M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) n/a 841.42M n/a n/a n/a n/a
Cash remaining n/a 3.14B n/a n/a n/a n/a
Runway (months of cash) n/a 11.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Sep 22 Steven M Rales Common Stock, par value $.01 Other Acquire J No No 276.05 28,280 7.81M 1,145,789
9 Sep 22 Christopher Bouda Danaher Deferred Compensation Programs - Danaher Stock Fund Common Stock Grant Acquire A No No 290.42 9.436 2.74K 1,911.884
26 Aug 22 Christopher Bouda Danaher Deferred Compensation Programs - Danaher Stock Fund Common Stock Grant Acquire A No No 280.33 9.776 2.74K 1,902.448
15 Aug 22 Blair Rainer Common Stock Sell Dispose S No Yes 300 25,000 7.5M 79,739
15 Aug 22 Blair Rainer Common Stock Option exercise Acquire M No No 70.75 5,655 400.09K 104,739
15 Aug 22 Blair Rainer Common Stock Option exercise Acquire M No No 65.83 19,345 1.27M 99,084
15 Aug 22 Blair Rainer Employee stock option Common Stock Option exercise Dispose M No No 70.75 5,655 400.09K 15,792
15 Aug 22 Blair Rainer Employee stock option Common Stock Option exercise Dispose M No No 65.83 19,345 1.27M 0
12 Aug 22 Christopher Bouda Danaher Deferred Compensation Programs - Danaher Stock Fund Common Stock Grant Acquire A No No 297.75 9.204 2.74K 1,892.672
29 Jul 22 Blair Rainer Danaher Deferred Compensation Programs - Danaher Stock Fund Common Stock Grant Acquire A No No 291.47 8.778 2.56K 10,242.821
13F holders Current Prev Q Change
Total holders 1951 1981 -1.5%
Opened positions 135 125 +8.0%
Closed positions 165 169 -2.4%
Increased positions 755 781 -3.3%
Reduced positions 776 786 -1.3%
13F shares Current Prev Q Change
Total value 141.1B 163.11B -13.5%
Total shares 557.46M 556.39M +0.2%
Total puts 2.13M 2.66M -19.6%
Total calls 1.72M 1.93M -10.7%
Total put/call ratio 1.2 1.4 -10.0%
Largest owners Shares Value Change
Vanguard 52.69M $13.36B +3.3%
BLK Blackrock 47.56M $12.06B +4.7%
STT State Street 26.7M $6.78B +2.1%
TROW T. Rowe Price 26.44M $6.7B -5.9%
FMR 25.51M $6.47B +0.8%
Wellington Management 18.97M $4.81B +4.9%
MS Morgan Stanley 16.94M $4.3B +25.4%
Massachusetts Financial Services 12M $3.04B -3.6%
Geode Capital Management 11.1M $2.81B +3.9%
BAC Bank Of America 11.02M $2.79B -14.4%
Largest transactions Shares Bought/sold Change
MS Morgan Stanley 16.94M +3.43M +25.4%
Parametric Portfolio Associates 0 -2.56M EXIT
BLK Blackrock 47.56M +2.13M +4.7%
BAC Bank Of America 11.02M -1.85M -14.4%
Vanguard 52.69M +1.69M +3.3%
TROW T. Rowe Price 26.44M -1.65M -5.9%
Jennison Associates 6.98M +1.33M +23.6%
JPM JPMorgan Chase & Co. 3.54M +1.07M +43.2%
Citadel Advisors 87.45K -958.74K -91.6%
Manufacturers Life Insurance Company, The 4.24M -953.49K -18.4%

Financial report summary

?
Risks
  • The COVID-19 pandemic has adversely impacted, and may continue to adversely impact, certain elements of our business and our financial statements.
  • We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
  • Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation.
  • The health care industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
  • International economic, political, legal, compliance, social and business factors can negatively affect our business and financial statements.
  • Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
  • Certain of our businesses rely on relationships with collaborative partners and other third-parties for development, supply and marketing of certain products, potential products and technologies, and such collaborative partners or other third-parties could fail to perform sufficiently.
  • Any inability to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, could negatively impact our business.
  • Our acquisition of businesses, investments, joint ventures and other strategic relationships can negatively impact our business and financial statements.
  • The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
  • Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have disposed could adversely affect our business and financial statements.
  • Potential indemnification liabilities pursuant to the Communications Disposition, the Fortive Disposition or the Envista Disposition could adversely affect our business and financial statements.
  • We could incur significant liability if any of the Communications Disposition, the Fortive Disposition or the Envista Disposition is determined to be a taxable transaction.
  • Significant disruptions in, or breaches in security of, our information technology systems or data or violation of data privacy laws can adversely affect our business and financial statements.
  • Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
  • If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed.
  • Climate change, or legal or regulatory measures to address climate change, may negatively affect us.
  • The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.
  • If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our business and financial statements may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services can cause production interruptions, delays and inefficiencies.
  • Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners can adversely affect our business and financial statements.
  • Our financial results are subject to fluctuations in the cost and availability of the supplies that we use in, and the labor we need for, our operations.
  • Our success depends on our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets.
  • Our restructuring actions can have long-term adverse effects on our business and financial statements.
  • Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and results of operations.
  • If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to the United States.
  • Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
  • The U.S. government has certain rights with respect to incremental production capacity and/or the intellectual property we have developed using government financing.
  • Our outstanding debt has increased significantly as a result of acquisitions, and we may incur additional debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements.
  • We may be required to recognize impairment charges for our goodwill and other intangible assets.
  • Foreign currency exchange rates can adversely affect our financial statements.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In addition, audits by tax authorities can result in additional tax payments for prior periods.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Legal, political, and economic uncertainty surrounding the exit of the United Kingdom from the EU could have an adverse effect on our business and financial statements.
  • Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements.
  • Significant developments or changes in U.S. laws or policies can have an adverse effect on our business and financial statements.
  • Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
  • Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
  • We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
  • Certain of our businesses are subject to extensive regulation by the FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.
  • Our products can be subject to human clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market, and could adversely affect our business and financial statements.
  • Off-label marketing of our products could result in substantial penalties.
  • Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
  • Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.
  • Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
  • Exclusive forum provisions in our By-laws could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers or employees.
Management Discussion
  • Total sales increased 7.5% and 9.5% during the three and six-month periods ended July 1, 2022 compared to the three and six-month periods ended July 2, 2021, respectively, primarily as a result of the increase in core sales resulting from the factors discussed below by segment as well as an increase in sales from acquired businesses. The impact of currency translation decreased reported sales 4.5% and 3.5% on a year-over-year basis during the three and six-month periods ended July 1, 2022, respectively, primarily due to the unfavorable impact of the strengthening of the U.S. dollar against most other major currencies in 2022 compared to the comparable periods of 2021. Price increases contributed 4.0% and 3.0% to sales growth on a year-over-year basis during the three and six-month periods ended July 1, 2022, respectively, and are reflected as a component of core sales growth above.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: ASC, DBS, Italy, microbiology, repaid, shipping
Removed: artificial, Austria, computing, connectivity, digitization, instrument, intelligence, IRS, mobile

Patents

Utility
Microscope for Examination of a Sample and Corresponding Method of Operating Such a Microscope
29 Sep 22
A microscope for microscopic examination of a sample includes an illumination optics for illuminating the sample, an imaging optics for imaging the sample, a sample chamber for receiving the sample.
Utility
Controller and Method for Providing an Operational Setting of an Imaging Device
29 Sep 22
A controller for providing an operational setting of an imaging device is configured to provide a user with a preferred operational setting for acquiring an image.
Utility
Mixing system
27 Sep 22
The present invention relates to a mixing system for a bioreactor, comprising a plurality of supply units (10), each being able to hold media for use in a bioreactor a mixing unit (30) for creating a uniform mixing of media a first feeding mechanism (20), arranged to feed media from the supply units (10) into the mixing unit (30), a control unit (40) operatively connected to the first feeding mechanism (20) and the mixing unit (30), said control unit (40) being configured to control the first feeding mechanism (20) to feed predetermined amounts of media from the plurality of supply units (10) to the mixing unit (30), and further being configured to control the mixing unit (30) to create a uniform mixing of media.
Utility
Bioprocess system and method providing automated configuration detection
27 Sep 22
The present invention relates to a method of automated configuration in a bioprocess system (10) and to verify a process defined by a flow path representation.
Design
Laboratory device
20 Sep 22
Inventors: Patrick Grimmel